Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer's disease have been dented by the failure of a phase 2b trial of Johnson & Johnson's posdinemab. The AuTonomy ...
TIOBE Index for February 2026: Top 10 Most Popular Programming Languages Your email has been sent February’s TIOBE Index shows a leaderboard that looks steady at first glance, but small shifts beneath ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results